Author(s):
Nutan R. Zanjurne, Omkar A. Devade, Laxmikant M. Purane, Vivek K. Redasani
Email(s):
nutanzanjurne@gmail.com
DOI:
10.52711/2321-5836.2024.00053 
Address:
Nutan R. Zanjurne1*, Omkar A. Devade2, Laxmikant M. Purane2, Vivek K. Redasani3
¹Research Scholar, YSPM YTC, Satara, Maharashtra 415015, India.
2Department of Pharmacology, YSPM YTC, Satara Maharashtra 415015, India.
3Director and Principal, YSPM YTC, Satara Maharashtra 415015, India.
*Corresponding Author
Published In:
Volume - 16,
Issue - 4,
Year - 2024
ABSTRACT:
Due of its high death rate, cancer continues to be one of the biggest hazards to human health globally. Globally, it is estimated that there are 19.3 million new instances of cancer and approximately 10 million cancer-related deaths annually, the most prevalent malignancies diagnosed globally are lung and breast cancer, which also account for the majority of cancer-related deaths in men and women, respectively. Numerous cancer therapies are available, including hormone therapy, radiation therapy, chemotherapy, surgery, targeted therapy, immunotherapy, and bone marrow transplantation. All of these medicines are important in the treatment of cancer. Many malignancies are incurable and cannot be effectively treated with the medications that are currently on the market. The marine ecosystem has very lately come into existence alongside terrestrial resources. Drugs originating from marine sources fall into a wide variety of chemical types, such as hydroxyphenylactic acid derivatives, cyclodepsipeptides, polyketides, terpenes, and alkaloids. These substance able to stop the growth of human tumor cells through both in vitro and in vivo cancer cell pathways. The aquatic environment is a plentiful supply of anticancer medications. Marine chemicals have a wide range of qualities, including antibacterial, antidiabetic, antiviral, anti-inflammatory, and anticancer effects. An overview of the progress made in developing marine-derived chemicals for cancer treatment is given in this paper, along with potential future directions. We also mentioned about medications that are undergoing various stages of clinical trials as well as commercially available, potentially anticancer substances derived from marine sources.
Cite this article:
Nutan R. Zanjurne, Omkar A. Devade, Laxmikant M. Purane, Vivek K. Redasani. An Overview on Anticancer Drug extracted from Marine Sources. Research Journal of Pharmacology and Pharmacodynamics. 2024;16(4):306-4. doi: 10.52711/2321-5836.2024.00053
Cite(Electronic):
Nutan R. Zanjurne, Omkar A. Devade, Laxmikant M. Purane, Vivek K. Redasani. An Overview on Anticancer Drug extracted from Marine Sources. Research Journal of Pharmacology and Pharmacodynamics. 2024;16(4):306-4. doi: 10.52711/2321-5836.2024.00053 Available on: https://rjppd.org/AbstractView.aspx?PID=2024-16-4-9
REFERENCE:
1. D. D. Rishipathak, A. B. Kokate, K. S. Madhawai. Activity of Quinazoline Derivatives: A Review. Asian J. Res. Pharm. Sci. 2017; 7(4): 209-211. doi: 10.5958/2231-5659.2017.00032.7
2. Pravin Kumar, Mahendra Singh Ashawat, Vinay Pandit. Gold Nanoparticle-Small Drug Molecule Conjugates: Therapeutic Applications and Benefits as Compared to Free Drug. Asian J. Pharm. Tech. 2018; 8(1): 52-62. doi: 10.5958/2231-5713.2018.00009.0
3. Baldev Krishan Sharma. Synthetic and Natural Compounds as Anti-Cancer Agents – A Review. Asian J. Research Chem., 2017; 10(5): 699-707. doi: 10.5958/0974-4150.2017.00119.5
4. Rohit Bhatia, Kiran Thapliyal, Dharmendra Kumar. Phytochemical and Therapeutic Aspects of Morinda citrifolia L. (Noni Plant) Research Journal of Pharmacognosy and Phytochemistry. 2015; 7(3).
5. Seth A.K., Shah B., Textbook of Pharmacognosy and Phytochemistry, published by Elsevier Inc. India Private Limited, 2010; 14(29): 462.
6. Faitrcloth G., Jimeno J., Rinehart K., Scheur P., Sousa- faro J.M.F., New Marine Anticancer Therapeutics- A journey from the sea to clinical trials, Mar.Drugs, 2015; 2: 15.
7. Emma Marris, Reporter for Nature Science, News Paper, Drugs From the Deep, 2006; 443.
8. Jiang S., Ke Ye, Wu L., Zhou G., Marine Power on Cancer: Drugs, Lead Compounds and Mechanisms, Mar. Drugs. 2021; 19(488): 1.
9. Newmann T., Fact checked by Isabel Godfrey, Why scientists are searching the ocean for new drugs, Medical News Today. 2019; 1.
10. Choi Y.H., Kim G.Y., Kim W.J., and Pectenotoxin-2 from marine sponges: A Potential and Anticancer Agent, Mar. Drugs. 2011; 2176-2187: 2184.
11. Jankiram N.B., Mohammad A., Rao C.V., Sea Cucumbers Metabolites as a Potent Anticancer Agents, Mar. Drugs. 2015; 2909-2923: 2910.
12. Dyshlovoy S.A., Honecker F., Marine compounds and cancer: The First Two Decades of XXI Century, Mar. Drugs. 2015; 20(1-4): 1.
13. Hemalatha C N, Anbarasu K, Vijey Aanandhi M. Evaluation of Anti-Cancer and Anti-Oxidant Activity of Cissus quandrangularis Extracts in DMBA induced Mammary Carcinomas. Research J. Pharm. and Tech. 2017; 10(1): 293-300. doi: 10.5958/0974-360X.2017.00060.9
14. B. Edwin Jose, P. Muralidharan. Effect of Azima tetracantha Lam on Human Breast Cancer Cells MCF-7. Research J. Science and Tech. 2019; 11(2): 109-112. doi: 10.5958/2349-2988.2019.00017.2
15. Raghad J. Fayyad, Alaa Naseer Mohammed Ali, Noor T. Hamdan. The Specific Anti-cancerous Mechanisms Suggesting Spirulina Alga as a Promising breast Cancer Fighter. Research Journal of Pharmacy and Technology. 2021; 14(10): 5599-2. doi: 10.52711/ 0974-360X.2021.00974
16. Bishnu Prasad Sahu, Bibekananda Meher, Biplob Kumar Dey. Exploration of Bryophytes for its Therapeutic Potential. Research J. Pharm. and Tech. 2021; 14(2): 1099-1103. doi: 10.5958/0974-360X.2021.00198.0
17. Gul-e-Saba Chaudhry, Muhammad Naveed Zafar, Yeong Yik Sung, Tengku Sifzizul Tengku Muhammad. Phytochemistry and Biological activity of Vitex rotundifolia L. Research J. Pharm. and Tech. 2020; 13(11): 5534-5538. doi: 10.5958/0974-360X.2020.00966.X
18. Rajasekhar Pinnamaneni. Cell Viability Studies and Anti-cancerous activity Evaluation of Pomegranate (Punica granatum L) extract . Research J. Pharm. and Tech. 2020; 13(1): 303-307. doi: 10.5958/0974-360X.2020.00061.X
19. Michael Lam. Beating Cancer with Natural Medicines, Library of Congress Control Number. 2003; 56.
20. Alajlani M., Al- Mousawi S.M., Chang F.R., Chen L., Elias N., El-seedi H.R., El- wahad A.A., Farag M. A.,. Goransson Ulf, Hegazy M.E.F., Iwasaki A., Khalifa S.A.M., Moustafa M.S. Musharraf S.G., Saeed A., Suenaga K., Marine Natural Products: A source of Novel Anticancer Drugs, Mar.Drugs. 2019; 17(491): 1-33.
21. Andrianasolo E., Flatt P., Gerwick W.H., McPhail K., Simmons T. L. Marine natural products as anticancer drugs. American Association for Cancer Research Journals Molecular Cancer Therapeutics. 2005; 4(2).
22. Haefner B. Drugs from the deep: Marine natural products as drug candidates. Drug Discovery Today. 2003; 8(12): 536 – 544.
23. Malve H. Exploring the ocean for new drug development: Marine Pharmacology, Journal of Pharmacy and Bioallied Sciences. 2016; 8(2): 83.
24. Liu Z.D., Wang N., Wang N., Wang T., Wang Z., Zhang B., Zhang Q.T., Zhao Y.F. Recent Advances in small peptides of Marine origin in cancer therapy, Marine Drugs. 2021; 19(2): 115.
25. Buffalo A.D, Fini M., Russo P. Deepsea as a source of novel anticancer drugs: update on discovery and preclinical/clinical evaluation in a systems medicine perspective. Experimental and Clinical Science Journal. 2015; 14: 228 – 236.
26. Anderson J.L., Assaraf Y.G., Cloos J., Jansen G., Kale A.J. Kaspersky G.J.L., Meerloo J.V., Moore B.S., Niewerth D., Riethoff L.F.V., Zweegman S., Antileukemic activity and mechanism of drug Resistance to the marine Salinospora Tropica Proteasome inhibitor Salinosporamide A [Marizomib]. American Society for Pharmacology and Experimental Therapeutics Journal.,00 Molecular Pharmacology. 2014; 86(1): 12-19.
27. Lam K.S., Potts B.C. Generating a generation of Proteasome inhibitors: From Microbial Fermentation to total Synthesis of Salinosporamide A [Marizomib] and other Salinosporamides. Marine Drugs. 2010; 8(4): 835 – 880.
28. Ali J.A., Chao T.H., Groll M., Lloyd K., Macherla V.R., Manama R.R., McArthur K.A., Neuteboom S.T.C., Palladino M.A., Palombella V.J., Potts B.C.M. Leaving groups prolong the Duration of 20s Proteasome inhibition and Enhance the Potency of Salinosporamides. Journal of Medicinal Chemistry. 2008; 51(21): 6711 – 6724.
29. Kumar S., Rajan A.M. New Investigational Drugs with Single agent activity in Multiple Myeloma. Blood Cancer Journal. 29 July 2016; 6(7): e451. Doi: 10.1038/ bcj.2016.53.
30. Cavalli A., Decherchi S., Diaz J.F., Huang L., Lloyd K., Olieric N., Perez F.D.A.B., Sala G.L., Sharma A., Steinmetz M.O., Tonra J.R., Viti F. Structure, Thermodynamics and Kinetics of PlinabulinBinding to two Tubulin Isotopes. Journal of Chemistry. 2019; 5(11): 2969 – 2986.
31. Kwok H.F., Zuo W. Development of Marine Derived Compounds for Cancer Therapy. Marine Drugs. 2021; 19(6): 342. https://doi.org/10.3390/md19060342.
32. Ashton E., Cropp G., Federico K.C., Heath E.I., Lloyd K., LoRusso P.M., Malburg L., Mita A.C., Mita M.M., Neuteboom S.T.C., Papadopoules K.P., Pilat M.J., Reich S.D., Romero O., Spear M.A., Yee L.K. Phase I first– in- human trial of the vascular Disrupting agent Plinabulin [NPI-2358] in patients with solid tumors or Lymphomas. Clinical Cancer Research. 2010; 16(23): 5892 – 5899.
33. Newman D.J. The utility of Highly toxic Marine – Sourced Compounds. Marine Drugs. 2019; 17(6): 324. https://doi.org/10.3390/md17060324.
34. Liu Z.D., Wang N., Wang N., Wang T., Wang Z., Zhang B., Zhang Q.T., Zhao Y.F. Recent Advances in small peptides of Marine origin in cancer therapy. Marine Drugs. 2021; 19(2): 115.
35. Abdelnour S., Abdo M., Alagawany M., El-Hack M.E.A., Elnesr S.S., Gabriel M.G., Khafaga A.F., Mahgoub S.A., Sakr M.A. Microalgae in modern cancer therapy. Current knowledge, Biomedicine and Pharmacotherapy Journal. 2019; 111: 42-50.
36. Badr C.E., Dolan B.P., Ishmael J.E., Kawaguchi S., Kazemi S., Mattos D.R., McPhail K.L., Moasser M.M., Oishi S., Paavilainen V.O., Saenz A.R., Serrill J.D. Targeting of HER/ErbB family proteins usingbroad spectrum Sec61 inhibitors Coibamide A and Apratoxin A. Biochemical Pharmacology. 2021; 183: 114317.
37. Alley S.C., Breij E.C., Cao A., Dominguez T., Harris J.R., Heuvel E.G.V.d., Satijin D., Velayudhan J., Verploegen S., Abstract 221: Tisotumab vedotin induces Anti- tumor activity through MMAE – mediated, Fc – mediated and Vitro. Cancer Research. 2019; 79(13 supplement): 221-221.
38. Arkenau H.T., Bono J.S.d., Coleman R.L., Concin N., Cornez N., Drew Y., Forster M.D., GennigensC., Ghatta S., Harris J.R., Hong D.S., Johnson M.L., Jones R., Lassen U.N., Machiels J.P., Rangwala R.A., Slomovitz B.M., Spicer J.F., Thistelethwaite F.C., Vergote I., Windfeld K. Tisotumab vedotin in Previously treated Recurrent or metastatic cervical cancer. Clinical Cancer Research. 2020; 26(6): 1220.
39. Markham A. Tisotumab vedotin: First Approval. Drugs. 2021; 81: 2141 – 2147.
40. Argiles G., Betrian S., Coronado C., Delord J.P., Elez E., Fudio S., Iglesias J., Macarulla T., Pita A.S.M., Roca C.G., Tabernero J., Valentin T., Zaragoza K. First – in – human phase I study of the microtubule inhibitor Plocabulin in patients with advanced solid tumors. Investigating New Drugs. 2019; 37: 674 – 683.
41. Tamanna Rai, Niranjan Kaushik, Rishabha Malviya, Pramod Kumar Sharma. A review on marine source as anticancer agents. 2024; 26(4): 415-451.
42. Andrey J.M., Aviles P., Barasoain J., Bouchet B.P., Cuevas C., Diaz J.F., Diaz M.M., Fernandez L.F.G., Galmarini C.M., Leal J.F.M., Navarro M.J.G., Pera B., PM060184, a New tubulin binding agent with potent antitumor activity including p – glycoprotein over–expressing tumors. Biochemical Pharmacology. 2014; 88(3): 291 – 302.
43. Sousa M.L.D.S. Cyanobacterial Bioactive Metabolites for anticancer drug discovers: Characterization of New compounds and molecular Mechanisms in Physiologically relevant 3D cell culture, repositorio – aberto.up.pt. 2020.
44. Almany C., Basho R., Bono V., Cortes J., Diabs S., Dillon P., Eth J., Han H.H., Kuemmel S., Meisel J., Oliveira M., O‟Shaughnessy J., Papish S., Pluard T., Reasor E.S., Sanchez L.M., Sinha R., Sterrenberg D., Tsai M., Vazquez R.V., Wang Y., Wang Z., Wuerstlein R., Abstract PD1 – 06: Open label phase 1b/2study of Ladiratuzumab vedotin in combination with pembrolizumab for First – line treatment of patients with unresectable locally – advanced or metastatic triple – negative breast cancer. Cancer Research. 2020; 80[4 supplement]: PD1 – 06 - PD1–06.
45. Sousa R.B., Tolaney S.M. Clinical Development of new Antibody – Drug conjugate in breast cancer: To infinity and Beyond. BioDrugs. 2021; 35: 159 – 174.
46. Wu L.; Ye K.; Jiang S.; Zhou G. Marine Power On Cancer: Drugs, Lead Compounds, and Mechanisms. Mar. Drugs. 2021; 19: 488, 1-19.
47. Zuo W.; Kwok H.F. Development of Marine- Derived Compounds for Cancer Therapy. Mar. Drugs. 2021; 19: 342,1-26.
48. Sung H.; Ferlay J.; Siegel R L.; Laversanne M; Soerujomataram I.; Jemal A.; Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021; 71: 209-249.
49. Kanase HR.; Singh KM. Marine Pharmacology Potential, Challenges, and Future in India. J Med Sci. 2018; 38: 49-53.
50. Jimenez PC.; Wilke DV.; Costa-Lotufo LV. Marine Drugs for Cancer: Surfacing biotechnological innovations from the oceans. Clinics. 2018; 73: 1-7.
51. Swami U.; Shah U.; Goel S. Eribulin in cancer treatment. Mar. Drugs. 2015; 13: 5016-5058.
52. Dyshlovoy S.A.; Honecker F. Marine Compounds and Cancer: updates 2020. Drugs. 2020; 18: 643,1-6.
53. Dyshlovoy S.A.; Honecker F. Marine Compounds and Cancer: The First Two Decades of XXI Century Mar. Drugs. 2019; 18(20): 1-4.
54. Deeks E.D. Polatuzumab Vedotin: First Global Approved Drugs, 2019; 79: 1467-1475.
55. Hanna K.S. Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma. Drugs. 2019; 80: 1-7.
56. Kwok H. F., Zip W., Development of Marine Derived Compounds for Cancer Therapy, Mar. Drugs. 2021; 19(342): 1-26.
57. LouRusso P., McLaughlin J., Department of Medical Oncology, Antibody drug conjugates: Fundamentals, Drug Development and Clinical Outcomes to Target Cancer, Edited by Hurvitz S. A., Oliver Jr., K. J.
58. Chouriri T. K., Croitoru R., George S., Heng D. Y. C., Jie F., Kollamanns B. C., Poondru S., Thompson J. A. Randomised phase II study of AGS-16C3F versus Antinixib in Previously Treated Patients with Metastatic Renal Cell Carcinoma. The Oncologist. 26(3): 182- e361.
59. National Cancer Institute at National Institute of Health [cancer. gov] 49 U.S. National Library of Medicine. Clinical Trials.gov.
60. Boria P., Draisci R., Giannetti L. L., Poletti R. First report of pectenotoxin-2 [PTX-2] in algae [Dinophysis fortii] related to seafood poisoning in Europe. 1996; 34(8): 923-935.
61. Luis M. Botana. Seafood and Freshwater Toxins Pharmacology, Physiology and Detection, second edition, Toshiyuki Suzuki, Chemistry, Metabolism and chemical Detection Methods of Pectenotoxins. 343- 356.
62. M. Eastman A. Higgs H. N., Micalizio G. C., Rourke N. F. Function Oriented Studies Targeting Pectenotoxin-2: Synthesis of the GH- Ring System and Structurally Simplified Macrolactone. Org. Lett. 2017; 19: 5154- 5157.
63. R Guzmán-Guillén, M Puerto, D Gutiérrez-Praena., Potential use of chemoprotectants against the toxic effects of cyanotoxins. Toxins. 2017; 9(6): 175.
64. Ana F.C., Ana G.R., Daurte A.C., Rocha- Santos T.A.P. Clinical Trials for deriving bioactive compounds from Marine Invertebrates, Natural Products In Clinical Trials. Volume-1, edited by Rahman A., Anjum S.FRS, El-seedi H., 1-30(30).
65. Akjon L.D., Sun M.K. Bryostatin-1: Pharmacology and Therapeutic Potential as a CNS Drug Rev. Spring. 2006; 12(1): 1-8.
66. Balounovo Z., Kollar P., Pazourek J., Rajchard J. Marine Natural Products: Bryostatins in preclinical studies. Pharm Biol. 2014; 52(2): 237- 242.
67. Barraja P., Barreca M., Bertoni F., Bilela L. L., Cueto M., Deniz I., Erdogon A., Gaudencio S. P., Marrero A. P. D., Mehri M., Montalbano A., Moulin C., Petale G., Rotter A., Spano V., Taffin-de- Givenchy E., Thomas O. P., Soriano F. Marine Anticancer Agents: An overview with a particular focus on their chemical classes, Mar. Drugs. 2020; 18(619): 1-28
68. D.M., Kortmansky J., Schwartz G.K. Bryostatin-1: A novel PKC Inhibitor in Clinical Development. Cancer Investigations. 2003; 21(6): 924-936.
69. Bauermeister A., Branco P. C., Costa- Lotufo L.V., Gaudencio S. P., Jimenez P. C., Rezende- Teixeira P., Wilke D. V. Enriching cancer pharmacology with drugs of marine origin. Br. J. Pharmacol. 2020; 177: 3-27.
70. M.L. Amador, J. Jimeno, L. Paz-Ares, M. Hidalgo Progress in the development and acquisition of anticancer agents from marine Sources. 2003; 14(11): 1607-1615.